Qiagen announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.
The agreement initially focuses on a companion diagnostic test for non-small cell lung cancer (NSCLC) and allows for further development of tests for other Mirati oncology programs.
The planned companion diagnostic would expand upon QIAGEN’s therascreen KRAS testing portfolio based on real-time qualitative PCR for the Qiagen Rotor-Gene Q MDx instrument, a member of the modular QIAsymphony family of automation solutions.
Qiagen and Mirati have previously partnered for the development of a companion diagnostic.
The therascreen-based companion diagnostic detects KRASG12C, a genetic mutation that is one of the most common KRAS alterations linked to cancer. The RAS gene family is the most frequently mutated oncogene in human cancer, with KRAS being the most prevalent driver mutation in NSCLC.
